Experience

Davis Polk advised the dealer managers in connection with cash tender offers for (i) any and all of Anthem’s 7.000% notes due 2019 and (ii) up to $836.347 million aggregate principal…

Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $5.5 billion in aggregate principal amount of senior notes,…

Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Included in the shares are 840,000…

Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million aggregate principal amount of its 6.50% notes due 2021. Headquartered…

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $402.5 million principal amount of its 1.375% convertible senior notes due…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $750 million aggregate principal amount of 2.750% senior notes due 2023, $1…

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…